HC Wainwright Weighs in on Oculis’ Q1 Earnings (NASDAQ:OCS)

Oculis Holding AG (NASDAQ:OCS) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Oculis in a report released on Monday, May 12th. HC Wainwright analyst Y. Chen anticipates that the company will earn ($0.46) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Oculis’ Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.40) EPS and Q4 2026 earnings at ($0.40) EPS.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.26). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. The business had revenue of $0.32 million for the quarter, compared to the consensus estimate of $0.22 million.

OCS has been the topic of a number of other research reports. Robert W. Baird increased their price objective on shares of Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a report on Thursday, March 13th. Chardan Capital raised their price target on shares of Oculis from $28.00 to $33.00 and gave the company a “buy” rating in a research note on Friday, May 9th.

Oculis Trading Up 0.9%

NASDAQ:OCS opened at $17.76 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. The firm has a market capitalization of $775.44 million, a P/E ratio of -9.20 and a beta of 0.27. Oculis has a 12-month low of $10.79 and a 12-month high of $23.08. The business has a 50 day simple moving average of $17.99 and a 200 day simple moving average of $18.40.

Hedge Funds Weigh In On Oculis

A number of institutional investors and hedge funds have recently bought and sold shares of OCS. SR One Capital Management LP bought a new position in shares of Oculis in the first quarter valued at approximately $6,137,000. Aberdeen Group plc raised its position in Oculis by 24.1% in the first quarter. Aberdeen Group plc now owns 1,253,119 shares of the company’s stock worth $23,847,000 after acquiring an additional 243,695 shares in the last quarter. Kestra Private Wealth Services LLC bought a new position in shares of Oculis during the 1st quarter valued at about $234,000. Citadel Advisors LLC bought a new position in shares of Oculis during the 4th quarter valued at about $389,000. Finally, Bank of America Corp DE grew its stake in shares of Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after purchasing an additional 10,667 shares during the last quarter. Institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.